Result of Annual General Meeting

Jun 10, 2020

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

RNS Number : 5498P
Advanced Medical Solutions Grp PLC
10 June 2020
 

10 June 2020

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

 

Result of Annual General Meeting

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that at the Company’s Annual General Meeting held today at 11am at the Group’s offices in Winsford, Cheshire, CW7 3RT, all resolutions were duly passed. In line with the UK Government’s latest guidelines on social distancing due to COVID-19, AMS hosted its AGM as a closed meeting, with shareholders voting in advance by proxy. Further details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 18 May 2020.

 

Details of proxy votes received prior to the meeting will be made available on the Company’s website at www.admedsol.com. The poll results were as follows.

 

Resolution

 

For

Against

No. of shares

%

No. of shares

%

1

114,521,050

99.99

2,000

0.01

2

112,770,820

98.31

1,939,247

1.69

3

109,056,471

95.05

5,679,334

4.95

4

99,159,358

86.42

15,577,753

13.58

5

84,540,602

86.64

13,039,624

13.36

6

67,012,678

74.19

23,309,925

25.81

7

113,919,870

99.29

818,467

0.71

8

110,949,556

98.92

1,206,281

1.08

9

114,719,172

99.99

278

0.01

10

114,454,687

99.76

279,566

0.24

11*

109,047,649

95.08

5,640,944

4.92

12*

113,518,490

99.13

997,623

0.87

*Special Resolution

Notes:

1.  Votes “For” and “Against” are expressed as a percentage of votes received.

2.  A “Vote withheld” is not a vote in law and is not counted in the calculation of the votes “For” or “Against” a resolution.

3.  Total number of shares in issue at close of business on 8 June 2020 = 215,185,296 shares.  53.3% of the voting capital was instructed.

 

Ends –

 

For further information, please contact:

 

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer




Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Mary-Jane Elliott / Matthew Neal / Olivia Manser

AMS@consilium-comms.com



Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Daniel Adams / Patrick Robb / Gary Clarence


 

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, and internal fixation devices, which it markets under its brands LiquiBand®, RESORBA®, and LiquiBandFix8®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France.

 

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, and the Czech Republic, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has approximately 700 employees. For more information, please see www.admedsol.com.

.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 

END

 
 

RAGKKKBBKBKDFAD

For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.